PRESENTATION · Mar 2025 · PDF
Science
Explore conditions, clinical trials, and the latest research.
These pages contain non-exhaustive scientific information about uses of products that have not yet been approved by regulatory authorities, as their efficacy and safety for these uses have not yet been established. The information is provided for educational and scientific exchange purposes, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.
PRESENTATION · Mar 2025 · PDF
BBP-418 - MDA 2025 - Baseline Characteristics FORTIFY
PRESENTATION · Dec 2024 · PDF
Infigratinib - ISDS 2024 - Clinical Development Program Update
PRESENTATION · Dec 2024 · PDF
Encaleret - ADH1 - ASBMR 2024 Phase 2B Data over 24 Months
PRESENTATION · Dec 2024 · PDF
BBP-418 - WMS 2024 - FORTIFY Design
PRESENTATION · Dec 2024 · PDF
Canavan GTx BBP-812 - ESGCT 2024 - Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study
PRESENTATION · Dec 2024 · PDF
Acoramidis - AHA 2024 - Costs and healthcare resource utilization in ATTR-CM exceeds that of non-amyloid heart failure
PRESENTATION · Dec 2024 · PDF
BBIO - Infigratinib - PROPEL 2 Data Update and ACCEL Program Initiation
PRESENTATION · Dec 2024 · PDF